Docoh
Loading...

OPGN Opgen

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen is developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen's product portfolio includes Unyvero, Acuitas®AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

Company profile

Ticker
OPGN
Exchange
Website
CEO
Oliver Schacht
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
AdvanDx, Inc. • OpGen A/S • Crystal GmbH • Curetis GmbH • Curetis USA • Ares Genetics GmbH ...

OPGN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 Aug 21
19 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Opgen earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 31.73M 31.73M 31.73M 31.73M 31.73M 31.73M
Cash burn (monthly) 2.74M (positive/no burn) 2.36M 3.05M 2.53M 2.23M
Cash used (since last report) 10.04M n/a 8.64M 11.15M 9.26M 8.14M
Cash remaining 21.7M n/a 23.09M 20.58M 22.48M 23.59M
Runway (months of cash) 7.9 n/a 9.8 6.7 8.9 10.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Sep 21 Oliver Schacht Common Stock Buy Acquire P No No 3.08 5,000 15.4K 20,000
15 Sep 21 Johannes Bacher Common Stock Buy Acquire P No No 3.07 5,000 15.35K 25,000
10 Jun 21 Johannes Bacher Common Stock Buy Acquire P No No 2.3 9,394 21.61K 20,000
10 Jun 21 Johannes Bacher Common Stock Buy Acquire P No No 2.29 606 1.39K 10,606
10 Jun 21 Johannes Bacher Common Stock Buy Acquire P No No 2.25 10,000 22.5K 10,000
10 Jun 21 Oliver Schacht Common Stock Buy Acquire P Yes No 2.237 5,000 11.19K 5,000
10 Jun 21 Oliver Schacht Common Stock Buy Acquire P No No 2.25 720 1.62K 15,000
10 Jun 21 Oliver Schacht Common Stock Buy Acquire P No No 2.245 100 224.5 14,280
10 Jun 21 Oliver Schacht Common Stock Buy Acquire P No No 2.24 7,280 16.31K 14,180
10 Jun 21 Oliver Schacht Common Stock Buy Acquire P No No 2.23 3,800 8.47K 6,900

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

6.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 28 31 -9.7%
Opened positions 7 16 -56.3%
Closed positions 10 4 +150.0%
Increased positions 8 6 +33.3%
Reduced positions 8 4 +100.0%
13F shares
Current Prev Q Change
Total value 5.31M 5.06M +4.9%
Total shares 2.34M 2.03M +15.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 1.38M $3.14M +7.1%
Geode Capital Management 320.33K $727K +64.3%
BLK Blackrock 108.17K $246K +81.0%
STT State Street 101K $229K NEW
Renaissance Technologies 86.75K $197K +502.5%
NTRS Northern Trust 72.11K $164K +71.5%
Susquehanna Fundamental Investments 51.6K $117K NEW
Citadel Advisors 38.74K $88K -47.1%
Millennium Management 35.17K $80K NEW
Schonfeld Strategic Advisors 23.9K $54K -50.1%
Largest transactions
Shares Bought/sold Change
Geode Capital Management 320.33K +125.31K +64.3%
STT State Street 101K +101K NEW
Vanguard 1.38M +91.74K +7.1%
Renaissance Technologies 86.75K +72.35K +502.5%
Susquehanna Fundamental Investments 51.6K +51.6K NEW
National Asset Management 11.1K -48.53K -81.4%
BLK Blackrock 108.17K +48.42K +81.0%
Bayesian Capital Management 0 -47.9K EXIT
Millennium Management 35.17K +35.17K NEW
Citadel Advisors 38.74K -34.54K -47.1%

Financial report summary

?
Management Discussion
  • The Company’s total revenue for the year ended December 31, 2020 increased 20%, to $4.2 million from $3.5 million, when compared to the same period in 2019. This increase is primarily attributable to:
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: conclusion, COVID, flat, IDC, NaN, Pittsburgh, Qualitative, timeline, transplant, UPMC
Removed: customary, default, failure, Gaithersburg, good, involving, monthly, occasionally, prepayment, repay, suspended

Patents

APP
Utility
Methods for the Comprehensive Identification of Antimicrobial Resistance Markers by Sequencing
26 Aug 21
The present invention relates to the systematic identification of antimicrobial resistance markers (biomarkers) in a microorganism for a particular compound and the use of such identified markers for the screening of microorganisms for antimicrobial resistance, as well as for screening/predicting antimicrobial compounds that can overcome the resistance provided by one or more of the antimicrobial resistance marker(s).
GRANT
Utility
Methods of detecting multi-drug resistant organisms
28 Dec 20
The present invention provide methods using genes associated with multi-drug resistance for rapidly detecting a patient colonized or infected with an multi-drug resistant organism and administrating the appropriate precautions and/or treatment.
APP
Utility
Systems, Apparatus, and Methods for Generating and Analyzing Resistome Profiles
9 Sep 20
Systems, apparatus, and methods are disclosed for generating a resistome profile for a subject, monitoring an infection state of one or more subjects, and/or identifying a potential infection outbreak at a facility, for example, by obtaining first data representative of at least one measure of antibiotic resistance of an organism from a first sample, identifying the organism, determining at least one of an antibiotic susceptibility phenotype, an identity of an antibiotic resistance gene, and an antibiotic to which the organism is non-susceptible, generating and comparing a first pattern to at least one known pattern to determine and generate a profile uniqueness identifier indicating a degree of similarity above a threshold between the first pattern and the at least one known pattern.
GRANT
Utility
Systems, apparatus, and methods for generating and analyzing resistome profiles
11 Nov 19
Systems, apparatus, and methods are disclosed for generating a resistome profile for a subject, monitoring an infection state of one or more subjects, and/or identifying a potential infection outbreak at a facility, for example, by obtaining first data representative of at least one measure of antibiotic resistance of an organism from a first sample, identifying the organism, determining at least one of an antibiotic susceptibility phenotype, an identity of an antibiotic resistance gene, and an antibiotic to which the organism is non-susceptible, generating and comparing a first pattern to at least one known pattern to determine and generate a profile uniqueness identifier indicating a degree of similarity above a threshold between the first pattern and the at least one known pattern.